Tirzepatide Dosage: The Titration Schedule and Pharmacokinetics from the Trial Programme
The short version
Tirzepatide is given as a once-weekly subcutaneous injection — a small injection under the skin, not into a vein or muscle. The FDA-approved starting dose is 2.5 mg once weekly for the first four weeks. The dose is then increased in steps to help the body adjust and to reduce side effects. Most clinical trials tested three maintenance doses: 5 mg, 10 mg, and 15 mg. The maximum dose studied and approved is 15 mg once weekly. The molecule stays in the bloodstream for approximately five days before half of it is cleared, which is why once-weekly dosing is sufficient. This page describes what the clinical trial programme and FDA label document about tirzepatide dosage — it is not a dosing recommendation.
Tirzepatide dosage — the approved titration schedule
The Tirzepatide titration schedule documented in the FDA prescribing information begins at 2.5 mg once weekly for four weeks, then advances in approximately monthly increments to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg once weekly [12]. The stepwise escalation is the mechanism by which gastrointestinal tolerability is managed — dose-related nausea, vomiting, and diarrhoea are most pronounced at each new dose level and typically attenuate with continued exposure over two to four weeks.
The three maintenance doses tested across the SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programmes were 5, 10, and 15 mg once weekly. Efficacy was dose-dependent for both HbA1c reduction and body-weight reduction at all three doses. In SURMOUNT-1, mean weight changes at 72 weeks were -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo [4]. In SURPASS-2, HbA1c reductions were -2.01, -2.24, and -2.30 percentage points across the three doses [3].
Tirzepatide dose — pharmacokinetics and half-life
The approximately five-day elimination half-life of Tirzepatide is a product of its molecular design. The fatty-diacid modification — a C20 eicosanedioic acid chain attached via a linker — confers high albumin-binding affinity, dramatically slowing renal clearance and enabling once-weekly subcutaneous administration. In a phase 1 multiple-ascending-dose study in Japanese adults with type 2 diabetes (n=48), the plasma half-life of approximately five days was confirmed across doses [37]. A population pharmacokinetics analysis across the phase 3 programme further characterised tirzepatide exposure and supported once-weekly dosing [38].
Metabolism proceeds via proteolytic cleavage of the amino acid backbone, beta-oxidation of the C20 diacid moiety, and amide hydrolysis. Renal excretion accounted for approximately 66% of radiolabelled drug recovered in a human ADME study, with approximately 33% in faeces; intact tirzepatide was not observed in urine or faeces [39].
Hepatic impairment did not produce clinically meaningful changes in tirzepatide exposure warranting dose adjustment in a dedicated clinical pharmacology study [40].
Tirzepatide injection — route and stability
Tirzepatide injection is administered exclusively by the subcutaneous route in the approved formulation and across the full clinical trial programme. Subcutaneous (under the skin) injection into the abdomen, thigh, or upper arm is the documented approach. Intravenous or intramuscular administration has not been studied.
Marketed formulations are refrigerated. Clinical-trial product was provided as a subcutaneous solution. Specific reconstitution and storage parameters are formulation-dependent and outside the scope of the published efficacy literature. The FDA prescribing information is the authoritative reference for approved formulation handling [12].
In SURMOUNT-5, participants received the maximum tolerated dose — defined as 10 or 15 mg — rather than a fixed dose, reflecting that some participants tolerate 10 mg but not 15 mg [5].
Tirzepatide peptide — structural context
The term tirzepatide peptide refers to its molecular nature: a linear synthetic peptide of 39 amino acids. Its backbone is engineered from the native GIP hormone sequence, with specific amino acid substitutions that confer GLP-1 receptor affinity. The molecular formula is C225H348N48O68, with a molecular weight of 4,813.53 Da and a CAS number of 2023788-19-2. The ATC code is A10BX16.
This structural design distinguishes tirzepatide from the selective GLP-1 receptor agonists that preceded it: whereas those agents engage a single receptor, tirzepatide engages two distinct receptors with a single molecule, producing the dual incretin effect that drives its larger efficacy profile in head-to-head trials [1][2].